Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
150 hedge funds and large institutions have $932M invested in Merrimack Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 66 increasing their positions, 34 reducing their positions, and 19 closing their positions.
154% more call options, than puts
Call options by funds: $6.62M | Put options by funds: $2.61M
94% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 34
14% more capital invested
Capital invested by funds: $820M → $932M (+$112M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
1% less funds holding
Funds holding: 152 → 150 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$23.9M |
| 2 |
CC
Cannell & Co
New York
|
+$8.64M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.13M |
| 4 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
+$6.41M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$6.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7.66M |
| 2 |
Two Sigma Investments
New York
|
-$4.04M |
| 3 |
ACM
Alpha Capital Management
Austin,
Texas
|
-$3.17M |
| 4 |
SIM
Spark Investment Management
New York
|
-$2.59M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$1.83M |
MACK Hedge Fund Activity: Q2 2015 in Review
150 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q2 2015, worth a combined $932M — up 14% from $820M a quarter earlier.
Fund positioning in MACK was balanced in Q2 2015: 19 funds opened new positions, 19 closed out, 66 added to existing stakes and 34 trimmed.
The largest buyer was Westfield Capital Management, adding an estimated $23.9M. The largest seller was Millennium Management, cutting an estimated $7.66M.
- 150 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q2 2015, down from 152 in Q1 2015.
- Funds reported $932M of Merrimack Pharmaceuticals, Inc. stock for Q2 2015, up 14% quarter-over-quarter.
- 19 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q2 2015 and 19 closed out, a net change of 0 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q2 2015 was Westfield Capital Management, an estimated $23.9M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q2 2015 was Millennium Management, an estimated $7.66M sold.
Based on aggregated 13F filings for Q2 2015.